[go: up one dir, main page]

HUP9801214A2 - Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk - Google Patents

Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk

Info

Publication number
HUP9801214A2
HUP9801214A2 HU9801214A HUP9801214A HUP9801214A2 HU P9801214 A2 HUP9801214 A2 HU P9801214A2 HU 9801214 A HU9801214 A HU 9801214A HU P9801214 A HUP9801214 A HU P9801214A HU P9801214 A2 HUP9801214 A2 HU P9801214A2
Authority
HU
Hungary
Prior art keywords
recombinant viruses
gene therapy
cholesterol acyltransferase
viruses expressing
lecithin
Prior art date
Application number
HU9801214A
Other languages
English (en)
Inventor
Patrice Denefle
Nicolas Duverger
Martine Latta-Mahieu
Sandrine Seguret
Original Assignee
Rhone-Poulenc Rorer S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer S.A. filed Critical Rhone-Poulenc Rorer S.A.
Publication of HUP9801214A2 publication Critical patent/HUP9801214A2/hu
Publication of HUP9801214A3 publication Critical patent/HUP9801214A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

A találmány tárgyát őlyan hiányős rekőmbináns vírűsők képezik, amelyeka lecitin-kőleszterin acil-transzferázt (LCAT) vagy annak egy részétvagy ezek egy variánsát kódőló beépített gént tartalmaznak. Atalálmány tárgyát képezik még ezeket a vírűsőkat tartalmazógyógyszerkészítmények és alkalmazásűk diszlipőprőteinémiával kapcsőltbetegségek kezelésére vagy megelőzésére. ŕ
HU9801214A 1995-03-14 1996-03-12 Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy HUP9801214A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9502943A FR2731710B1 (fr) 1995-03-14 1995-03-14 Virus recombinants exprimant la lecithine cholesterol acyltransferase et utilisations en therapie genique

Publications (2)

Publication Number Publication Date
HUP9801214A2 true HUP9801214A2 (hu) 1998-08-28
HUP9801214A3 HUP9801214A3 (en) 2000-08-28

Family

ID=9477007

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9801214A HUP9801214A3 (en) 1995-03-14 1996-03-12 Recombinant viruses expressing lecithin-cholesterol acyltransferase, and uses thereof in gene therapy

Country Status (15)

Country Link
US (1) US20010014319A1 (hu)
EP (1) EP0815239A1 (hu)
JP (1) JPH11501518A (hu)
KR (1) KR19980703008A (hu)
AU (1) AU711381B2 (hu)
BR (1) BR9607757A (hu)
CA (1) CA2214010A1 (hu)
CZ (1) CZ286897A3 (hu)
FR (1) FR2731710B1 (hu)
HU (1) HUP9801214A3 (hu)
IL (1) IL117466A0 (hu)
NO (1) NO974179L (hu)
SK (1) SK124897A3 (hu)
WO (1) WO1996028553A1 (hu)
ZA (1) ZA961998B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636907T2 (de) 1995-11-09 2007-11-22 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Verwendung von lezithin-cholesterin-azetyltransferase für die behandlung von atherosklerose
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies
AU6748198A (en) 1997-04-11 1998-11-11 Takeda Chemical Industries Ltd. Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use
WO2002103384A1 (en) * 2001-06-19 2002-12-27 Star Bt Limited Location, communication and tracking systems
CN1671836B (zh) * 2002-06-18 2012-02-08 卫材R&D管理有限公司 用于基因治疗的原代培养脂肪细胞
CA2654608A1 (en) * 2006-06-07 2007-12-13 Reddy Us Therapeutics, Inc. Compositions and methods to enhance reverse cholesterol transport
AU2007265475B2 (en) 2006-06-26 2010-08-19 Amgen Inc. Methods for treating atherosclerosis
JPWO2008108344A1 (ja) * 2007-03-02 2010-06-17 セルジェンテック株式会社 Ｌｃａｔ欠損症の遺伝子治療用細胞並びに遺伝子治療用細胞組成物
EP3515480A1 (en) 2016-09-20 2019-07-31 Boehringer Ingelheim Vetmedica GmbH New swine influenza vaccine
US10329586B2 (en) 2016-09-20 2019-06-25 Boehringer Ingelheim Vetmedica Gmbh Canine adenovirus vectors
EA201990711A1 (ru) 2016-09-20 2019-09-30 Бёрингер Ингельхайм Ветмедика Гмбх Новый ehv сайт инсерции orf70
MY199909A (en) 2016-09-20 2023-11-29 Boehringer Ingelheim Vetmedica Gmbh Promoters

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8424757D0 (en) * 1984-10-01 1984-11-07 Pasteur Institut Retroviral vector
US5049488A (en) * 1985-11-08 1991-09-17 Genentech, Inc. Method and nucleic acid for the preparation of lecithin:cholesterol acyltransferase
US5252479A (en) * 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
PL179877B1 (pl) * 1993-07-13 2000-11-30 Rhone Poulenc Rorer Sa Zdefektowany replikacyjnie adenowirus, linia komórkowa do infekowania zdefektowanym adenowirusem oraz srodek farmaceutyczny PL PL PL PL PL PL PL PL PL PL

Also Published As

Publication number Publication date
ZA961998B (en) 1996-09-26
MX9706569A (es) 1997-11-29
NO974179D0 (no) 1997-09-10
CZ286897A3 (en) 1997-12-17
WO1996028553A1 (fr) 1996-09-19
BR9607757A (pt) 1999-01-26
JPH11501518A (ja) 1999-02-09
FR2731710B1 (fr) 1997-04-30
FR2731710A1 (fr) 1996-09-20
CA2214010A1 (fr) 1996-09-19
AU5008296A (en) 1996-10-02
IL117466A0 (en) 1996-07-23
KR19980703008A (ko) 1998-09-05
SK124897A3 (en) 1998-02-04
NO974179L (no) 1997-09-10
EP0815239A1 (fr) 1998-01-07
HUP9801214A3 (en) 2000-08-28
AU711381B2 (en) 1999-10-14
US20010014319A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
NO954466L (no) Adenovirale vektorer av animalsk opprinnelse samt deres anvendelse i genterapi
HUP9700603A1 (hu) Gyógyászati készítmény véralvadási zavarok kezelésére
CS553490A3 (en) Transdermal therapeutic system
HUP9801214A2 (hu) Lecitin-koleszterin acil-transzferázt kifejező rekombináns vírusok és génterápiában való felhasználásuk
DE69831971D1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
BR9608449A (pt) Vìrus recombinante defeituoso, adenovìrus, uso de um vìrus, e, composição farmacêutica.
DE60117615D1 (de) Arzneimittelkombinationen (z.b. chlorpromazin und pentamidin) zur therapie von neoplastischen erkrankungen
FR2704556B1 (fr) Virus recombinants et leur utilisation en thérapie génique.
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
HUP9800635A2 (hu) In vivo exogén transzfekcióra és expresszióra használható gyógyászati kombináció
ZA941426B (en) Recombinant viruses and their use in gene therapy
HUP9802423A2 (hu) Hiperproliferatív megbetegedések kombinált gyógyászati kezelése
HUP9901353A2 (hu) ACE-inhibitorok alkalmazása diszpepsziás tünetek kezelésére alkalmas gyógyszerkészítmény előállítására
EP0744176A3 (en) Methods for inhibiting bone loss
HK1002284A1 (en) Novel implant and novel vector for the treatment of acquired diseases
DK1133296T3 (da) Ny terapeutisk anvendelse af nicergolin
WO2001028535A3 (en) Pharmaceutical formulations comprising a combination of s-salmeterol and fluticasone propionate
ATE312179T1 (de) Serin-threonin-kinase enthaltendes mittel zur tumortherapie und tumordiagnose
FI956353L (fi) Farmaseuttiset valmisteet ja niiden käyttö etenkin neurodegeneratiivisten sairauksien hoidossa
HUP9901299A2 (hu) Attenuált, nemimmunogén poxvírusokból vagy parapoxvírusokból előállított multipotens parapox immunitást előidéző gyógyszerek használatának új indikációi
NO964894D0 (no) Rekombinante viruser, deres fremstilling samt anvendelse av genterapi
FR2778104B1 (fr) Utilisation d'un vecteur d'ions fluorure pour la preparation d'un medicament destine a la prevention ou au traitement de maladies associees a helicobacter pylori
UA37445A (uk) Протизапальний засіб
UA9672A (uk) Спосіб лікування деструктивних форм гострого панкреатиту